Cidara Therapeutics, Inc. (CDTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Jeffrey L. Stein.
CDTX tiene fecha de IPO 2015-04-15, 38 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $5.61B.
Cidara Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and commercializing long-acting anti-infective treatments for infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel echinocandin antifungal designed to treat and prevent invasive fungal infections such as candidemia and invasive candidiasis, which carry high mortality rates. Cidara also leverages its Cloudbreak platform to develop conjugate therapies for preventing and treating viral infections, including influenza, RSV, HIV, and COVID-19. Founded in 2012 and based in San Diego, California, the company was formerly known as K2 Therapeutics before rebranding to Cidara Therapeutics in 2014.
